These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

245 related items for PubMed ID: 23279695

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Renal response after high-dose melphalan and stem cell transplantation is a favorable marker in patients with primary systemic amyloidosis.
    Leung N, Dispenzieri A, Fervenza FC, Lacy MQ, Villicana R, Cavalcante JL, Gertz MA.
    Am J Kidney Dis; 2005 Aug; 46(2):270-7. PubMed ID: 16112045
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. High-dose therapy and autologous hematopoietic stem cell transplantation for patients with primary systemic amyloidosis: a Center for International Blood and Marrow Transplant Research Study.
    Vesole DH, Pérez WS, Akasheh M, Boudreau C, Reece DE, Bredeson CN, Plasma Cell Disorders Working Committee of the Center for International Blood and Marrow Transplant Research.
    Mayo Clin Proc; 2006 Jul; 81(7):880-8. PubMed ID: 16835967
    [Abstract] [Full Text] [Related]

  • 26. The Effect of Bone Marrow Plasma Cell Burden on Survival in Patients with Light Chain Amyloidosis Undergoing High-Dose Melphalan and Autologous Stem Cell Transplantation.
    Dittus C, Uwumugambi N, Sun F, Sloan JM, Sanchorawala V.
    Biol Blood Marrow Transplant; 2016 Sep; 22(9):1729-1732. PubMed ID: 27296954
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Autologous transplantation for primary systemic AL amyloidosis is feasible outside a major amyloidosis referral centre: the Calgary BMT Program experience.
    Chow LQ, Bahlis N, Russell J, Chaudhry A, Morris D, Brown C, Stewart DA.
    Bone Marrow Transplant; 2005 Oct; 36(7):591-6. PubMed ID: 16062177
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Oral mucositis in myeloma patients undergoing melphalan-based autologous stem cell transplantation: incidence, risk factors and a severity predictive model.
    Grazziutti ML, Dong L, Miceli MH, Krishna SG, Kiwan E, Syed N, Fassas A, van Rhee F, Klaus H, Barlogie B, Anaissie EJ.
    Bone Marrow Transplant; 2006 Oct; 38(7):501-6. PubMed ID: 16980998
    [Abstract] [Full Text] [Related]

  • 31. Heart transplantation in systemic (AL) amyloidosis: a retrospective study of eight French patients.
    Mignot A, Varnous S, Redonnet M, Jaccard A, Epailly E, Vermes E, Boissonnat P, Gandjbakhch I, Herpin D, Touchard G, Bridoux F.
    Arch Cardiovasc Dis; 2008 Sep; 101(9):523-32. PubMed ID: 19041836
    [Abstract] [Full Text] [Related]

  • 32. Modified high-dose melphalan and autologous SCT for AL amyloidosis or high-risk myeloma: analysis of SWOG trial S0115.
    Sanchorawala V, Hoering A, Seldin DC, Finn KT, Fennessey SA, Sexton R, Mattar B, Safah HF, Holmberg LA, Dean RM, Orlowski RZ, Barlogie B.
    Bone Marrow Transplant; 2013 Nov; 48(12):1537-42. PubMed ID: 23852321
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Induction Therapy with Bortezomib Followed by Bortezomib-High Dose Melphalan and Stem Cell Transplantation for Light Chain Amyloidosis: Results of a Prospective Clinical Trial.
    Sanchorawala V, Brauneis D, Shelton AC, Lo S, Sun F, Sloan JM, Quillen K, Seldin DC.
    Biol Blood Marrow Transplant; 2015 Aug; 21(8):1445-51. PubMed ID: 25858810
    [Abstract] [Full Text] [Related]

  • 35. Induction therapy with bortezomib and dexamethasone followed by autologous stem cell transplantation versus autologous stem cell transplantation alone in the treatment of renal AL amyloidosis: a randomized controlled trial.
    Huang X, Wang Q, Chen W, Zeng C, Chen Z, Gong D, Zhang H, Liu Z.
    BMC Med; 2014 Jan 06; 12():2. PubMed ID: 24386911
    [Abstract] [Full Text] [Related]

  • 36. Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem-cell transplantation.
    Sanchorawala V, Skinner M, Quillen K, Finn KT, Doros G, Seldin DC.
    Blood; 2007 Nov 15; 110(10):3561-3. PubMed ID: 17673601
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. High-dose therapy with auto-SCT is feasible in high-risk cardiac amyloidosis.
    Kongtim P, Qazilbash MH, Shah JJ, Hamdi A, Shah N, Bashir Q, Wang M, Champlin R, Manasanch EE, Weber D, Orlowski RZ, Parmar S.
    Bone Marrow Transplant; 2015 May 15; 50(5):668-72. PubMed ID: 25730192
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.